BioCentury | Aug 7, 2020
Politics, Policy & Law

Latest executive order in spree to control biopharma centers on American-made drug products

An “America first” drug sourcing order signed Thursday is the latest in a series of attempts by President Donald Trump to bend the biopharma industry to his will in an effort to keep campaign promises...
BioCentury | Jul 28, 2020
Politics, Policy & Law

Trump’s ultimatum, RADx & preclinical IPOs: a BioCentury podcast

President Donald Trump’s ultimatum to biopharma CEOs to work with him on drug pricing hit its first hurdle when the executives declined an offer to meet at the White House on Tuesday. On the latest...
BioCentury | Jul 25, 2020
Politics, Policy & Law

Trump issues drug pricing ultimatum to biopharma CEOs

President Donald Trump Friday gave biopharma CEOs a choice: accept an international reference pricing scheme for biologics or propose an alternative that achieves the same goals. The ultimatum was issued at a White House event...
BioCentury | Jul 23, 2020
Politics, Policy & Law

White House backs testing, vaccines boost in coronavirus bill, to unveil drug pricing orders Friday

Senate Republican leaders and the White House have agreed to include tens of billions of dollars for COVID-19 vaccines in a coronavirus relief bill, according to a draft of agreement obtained by BioCentury. The agreement...
BioCentury | Jul 22, 2020
Politics, Policy & Law

White House drug pricing executive orders pushed back to August

The White House has again delayed the release of executive orders on drug pricing. The orders, which White House Chief of Staff Mark Meadows first publicly announced would be unveiled the week of July 6...
BioCentury | Jul 20, 2020
Politics, Policy & Law

PhRMA trying to water down White House drug pricing orders

...government would not pay more for drugs than the prices other developed countries pay, no-cost EpiPen...
BioCentury | Mar 19, 2019
Politics & Policy

Senate bill endorses Azar's call to allow drug imports

...steep price hikes seen in recent years with Daraprim pyrimethamine by Turing Pharmaceuticals AG and EpiPen...
BioCentury | Dec 4, 2018
Politics & Policy

Medicare bill aims to block drugmakers from misclassifying drugs

...The bill is in response to a lawsuit against Mylan N.V. (NASDAQ:MYL) for misclassifying its EpiPen...
BioCentury | Aug 31, 2018
Clinical News

Fast Track for Insys' nasal epinephrine

...with the agency this fall. Insys is developing the nasal spray as an alternative to EpiPen...
...on the market. Mylan has attracted criticism in recent years for hiking the price of EpiPen...
BioCentury | Aug 31, 2018
Clinical News

Teva wins first FDA approval for generic EpiPen

...ANDA from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) for the first generic version of EpiPen...
...for the emergency treatment of allergic reactions including anaphylaxis. Mylan N.V. (NASDAQ:MYL) markets the original EpiPen...
...on the market. Mylan has attracted criticism in recent years for hiking the price of EpiPen...
Items per page:
1 - 10 of 40